Living with MDS: Monitoring and Quality of Life
At a Glance
Living with Myelodysplastic Syndromes (MDS) involves routine blood count monitoring to track disease progression. Patients can improve their quality of life by preventing infections, managing transfusion-related iron overload, and addressing severe fatigue through supportive care.
Living with Myelodysplastic Syndromes (MDS) is often described as a “marathon, not a sprint.” Because the disease is chronic, your focus will likely shift from the initial shock of diagnosis to the day-to-day management of symptoms and the emotional toll of constant monitoring [1].
Understanding how to manage the long-term effects of the disease—and the treatments—can help you regain a sense of control over your life.
Routine Monitoring and “Scan Anxiety”
Monitoring is the foundation of MDS care. Your schedule will be tailored to your specific risk category (such as your IPSS-M score) [2].
- Blood Counts (CBC): You will likely have blood drawn every 1 to 4 weeks. These tests track your “trends”—how fast your red cells, white cells, and platelets are falling [3].
- Bone Marrow Biopsies: Unlike blood tests, these are not usually done on a fixed schedule. They are typically reserved for when your blood counts change significantly or to see how well a new treatment is working [4].
- Managing Anxiety: The cycle of testing and waiting for results can lead to “scan anxiety.” Sharing your results promptly and having a clear “red flag” plan can help lower this stress [5].
Daily Infection Prevention
If your white blood cell count is persistently low (neutropenia), taking smart daily precautions is essential to protect your health without completely isolating yourself [6].
- Hygiene and Exposure: Wash your hands frequently and consider wearing a well-fitting mask in crowded public spaces or medical waiting rooms.
- Socializing: You can absolutely still enjoy time with your family and grandchildren. However, it is wise to avoid close contact with anyone who is currently sick with a cold, fever, or stomach virus.
- Diet: Ask your care team if you need to adhere to a “neutropenic diet,” which often involves avoiding high-risk raw foods like sushi, unpasteurized dairy, or unwashed raw fruits and vegetables to prevent foodborne illness.
Managing Transfusions and Iron Overload
If you have lower-risk MDS, you may eventually require regular red blood cell transfusions to manage anemia [7]. While these transfusions provide much-needed oxygen and energy, they also carry a hidden cargo: iron.
Because the body has no natural way to get rid of excess iron, it can build up in your organs—a condition called iron overload [8][9].
- Monitoring Iron: Your doctor will track a protein called ferritin in your blood. If it gets too high, they may order an MRI T2*, a specialized scan that measures iron levels in your liver and heart more accurately than a blood test [10][11].
- Chelation Therapy: If your iron levels become dangerous, you may be prescribed chelation therapy (such as deferasirox). These medications “bind” to the iron so your body can flush it out [12]. Be aware that oral iron chelation therapies frequently cause significant gastrointestinal upset, which is a common quality-of-life issue you should discuss with your care team to help manage [12]. Since these drugs can affect the kidneys, regular blood tests to check your creatinine levels are also a standard part of this treatment [13].
Quality of Life and Self-Care
Fatigue is the most common and often the most frustrating symptom of MDS [1]. It is not the same as being “tired”—it is a deep, systemic exhaustion.
- Supportive Care: Palliative care is not just for the end of life; it is a specialty focused on symptom relief and quality of life [5]. Integrating it early can help manage pain, fatigue, and the psychological burden of the disease.
- Movement as Medicine: It may feel counterintuitive when you are exhausted, but low-impact exercise and specialized programs like yoga have been shown to significantly improve energy levels and emotional health in MDS patients [14][15].
“Red Flags”: When to Call Your Doctor
You are the best expert on your own body. Contact your care team immediately if you notice:
- Fever: If you have low white blood cells (neutropenia), any temperature over 100.4°F (38°C) is a medical emergency, as your body cannot fight off infections on its own [6]. Ask your doctor if you are currently in this danger zone.
- Unexplained Bleeding: New bruising, tiny red spots on the skin (petechiae), or bleeding gums [7].
- Sudden Change in Breathing: Increased shortness of breath or chest pain [10].
- Rapid Decline: A sudden, steep drop in your energy level that may signal the disease is changing [16].
Common questions in this guide
How often do I need blood tests for MDS?
What is considered a dangerous fever if I have MDS?
What is iron overload and why does it happen?
How is iron overload treated in MDS?
Should I exercise if I have severe fatigue from MDS?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.How often do we need to check my blood counts (CBC) to safely monitor my disease?
- 2.At what point would you recommend a repeat bone marrow biopsy to see if my MDS has changed?
- 3.What is my current ferritin level, and do I need an MRI T2* to check for iron in my liver or heart?
- 4.If I start iron chelation therapy, how will we monitor my kidney function to prevent side effects?
- 5.Can you refer me to a physical therapist or a supportive care specialist to help me manage this fatigue?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (16)
- 1
Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study.
Stauder R, Yu G, Koinig KA, et al.
Leukemia 2018; (32(6)):1380-1392 doi:10.1038/s41375-018-0089-x.
PMID: 29572506 - 2
Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
American journal of hematology 2023; (98(8)):1307-1325 doi:10.1002/ajh.26984.
PMID: 37288607 - 3
How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms.
Gurnari C, Xie Z, Zeidan AM
Clinical hematology international 2023; (5(1)):8-20 doi:10.1007/s44228-022-00024-4.
PMID: 36574201 - 4
Morphologic Characteristics of Myelodysplastic Syndromes.
Yuen LD, Hasserjian RP
Clinics in laboratory medicine 2023; (43(4)):577-596 doi:10.1016/j.cll.2023.06.003.
PMID: 37865504 - 5
Understanding the evolving role of early palliative care in myelodysplastic syndromes: a 2026 narrative review.
Niscola P, Gianfelici V, Giovannini M, et al.
Annals of hematology 2026; (105(5)).
PMID: 42081107 - 6
Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine.
Radsak M, Platzbecker U, Schmidt CS, et al.
European journal of haematology 2017; (99(2)):112-118 doi:10.1111/ejh.12883.
PMID: 28321924 - 7
Outpatient transfusions for myelodysplastic syndromes.
Wood EM, McQuilten ZK
Hematology. American Society of Hematology. Education Program 2020; (2020(1)):167-174 doi:10.1182/hematology.2020000103.
PMID: 33275745 - 8
Clinical features and outcomes of myelodysplastic syndrome patients with iron overload: a single-center retrospective study.
Huang L, Wang Y, Zhang X, et al.
European journal of medical research 2025; (30(1)):600 doi:10.1186/s40001-025-02848-1.
PMID: 40635108 - 9
Iron overload regulate the cytokine of mesenchymal stromal cells through ROS/HIF-1α pathway in Myelodysplastic syndromes.
Hu J, Meng F, Hu X, et al.
Leukemia research 2020; (93()):106354 doi:10.1016/j.leukres.2020.106354.
PMID: 32380365 - 10
Iron Overload in Chronic Kidney Disease: Less Ferritin, More T2*MRI.
Nashwan AJ, Yassin MA, Mohamed Ibrahim MI, et al.
Frontiers in medicine 2022; (9()):865669 doi:10.3389/fmed.2022.865669.
PMID: 35386917 - 11
The role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromes.
Petrou E, Mavrogeni S, Karali V, et al.
Revista brasileira de hematologia e hemoterapia 2015; (37(4)):252-8.
PMID: 26190429 - 12
Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome.
Escudero-Vilaplana V, Garcia-Gonzalez X, Osorio-Prendes S, et al.
Journal of clinical pharmacy and therapeutics 2016; (41(1)):59-63 doi:10.1111/jcpt.12348.
PMID: 26778738 - 13
CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload.
Bruch HR, Dencausse Y, Heßling J, et al.
Oncology research and treatment 2016; (39(7-8)):424-31 doi:10.1159/000447035.
PMID: 27486873 - 14
Effects of a home-based exercise program on physical capacity and fatigue in patients with low to intermediate risk myelodysplastic syndrome-a pilot study.
Schuler MK, Hentschel L, Göbel J, et al.
Leukemia research 2016; (47()):128-35.
PMID: 27326698 - 15
Kundalini Yoga for Improving Patient-Reported Outcomes in Patients Diagnosed with Myelodysplastic Syndromes: A Pilot Study.
Amitai I, Marcus R, Amitai Y, et al.
Acta haematologica 2025; 1-6 doi:10.1159/000547575.
PMID: 40875697 - 16
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
Garcia-Manero G, Chien KS, Montalban-Bravo G
American journal of hematology 2020; (95(11)):1399-1420 doi:10.1002/ajh.25950.
PMID: 32744763
This page provides information on managing Myelodysplastic Syndromes (MDS) for educational purposes only. Always consult your hematologist or oncologist for personalized medical advice regarding monitoring schedules and treatment plans.
Get notified when new evidence is published on Myelodysplastic syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.